Faculty of Medicine教員紹介:櫻井 準

氏名
櫻井 準
サクライ ヒトシ SAKURAI, Hitoshi
職位講師
所属教室精神神経科学
専攻・専門分野
 (大学院)
内科系専攻 精神神経科学分野
専門分野臨床精神医学全般(特に気分障害)、精神科薬物療法
研究テーマなかなか良くならないうつ病におけるケタミン治療
略歴出身大学 慶應義塾大学医学部 平成19年卒業
留学経験 アメリカ マサチューセッツ総合病院
所有する学位博士(医学)
指導医・専門医・認定医、その他の資格等精神保健指定医
日本精神神経学会精神科専門医・指導医
日本臨床精神神経薬理学会専門医・指導医
論文・著書等を含む主要研究業績 1. Sakurai H, et al. Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. Pharmacopsychiatry (in press)
2. Sakurai H, et al. Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Non-response to Acute Intravenous Ketamine Treatment. J Clin Psychopharmacol 42(2):140-145, 2022
3. Sakurai H, et al. Residual symptoms after achieving remission with repetitive transcranial magnetic stimulation in depression. J Affect Disord 301:154-161, 2022
4. Sakurai H (co-first), et al. Validation of brief screening measures for depression and anxiety in young people with substance use disorders. J Affect Disord 282: 1021-1029, 2021
5. Sakurai H, et al. Long-term Outcome in Outpatients with Depression Treated with Acute and Maintenance Intravenous Ketamine: A Retrospective Chart Review. J Affect Disord 276: 660-666, 2020
6. Sakurai H, et al. Pharmacological Management of Bipolar Disorder: Japanese Expert Consensus. Bipolar Disord 22(8): 822-830, 2020
7. Sakurai H, et al. Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry 54(2): 60-67, 2021
8. Sakurai H, et al. Pharmacological Management of Depression: Japanese Expert Consensus. J Affect Disord 266: 626-632, 2020
9. Sakurai H, et al. A Patient with Electroconvulsive Therapy-Resistant Major Depressive Disorder with a Full Response to Heated Yoga: A Case Report. J Psychiatr Pract 27(6): 486-491, 2021
10. Sakurai H, et al. A Patient with Treatment-resistant Depression Who Achieved Remission with Heated Yoga: A Case Report. Clinical Neuropsychopharmacology and Therapeutics 12: 12-17, 2021
11. Sakurai H et al. Improvement of Clinical Clerkship for Medical Students by Incorporating Ideas from Junior Residents: A Feasibility Study. Asian J Psychiatry 44: 110-111, 2019
12. Sakurai H (co-first), et al. Predicting Relapse with Residual Symptoms in Schizophrenia: Reappraisal of the PROACTIVE Trial. Schizophr Res 215: 173-180, 2020
13. Sakurai H, et al. Dose Increase of S-Adenosyl-Methionine and Escitalopram in a Randomized Clinical Trial for Major Depressive Disorder. J Affect Disord 262: 118-125, 2020
14. Sakurai H, et al. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord 258: 102-108, 2019
15. Sakurai H, et al. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Psychopharmacology (Berl) 234(16): 2453-2461, 2017
16. Sakurai H, et al. Increasing versus maintaining the dose of olanzapine or risperidone for schizophrenia patients who did not respond to modest dosage: a double-blind randomized controlled trial. J Clin Psychiatry 77(10): 1381-1390, 2016
17. Sakurai H, et al. Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord 151(2): 506-513, 2013
18. Sakurai H, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull 39(3): 564-574, 2013
所属学会日本精神神経学会
日本臨床精神神経薬理学会
日本神経精神薬理学会
日本うつ病学会

TEST